Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Impact
If established, the working group will include various stakeholders, such as mental health professionals, academics, and representatives from related organizations, to examine both the current landscape of laws and the scientific data surrounding psilocybin and psilocin. It plans to produce recommendations for regulatory frameworks that would enable the availability of safe, effective, and accessible psilocybin products for eligible adults. This initiative highlights Hawaii's effort to address mental health challenges facing its residents through innovative solutions, particularly in a context where there are reported shortages of mental health professionals.
Summary
SCR227 requests the Hawaii Department of Health to convene a Medicinal Psilocybin and Psilocin Working Group to study the medicinal and therapeutic benefits of psilocybin and psilocin, which are naturally occurring compounds in certain mushrooms. The goal of the working group will be to evaluate existing laws and regulations governing the medicinal use of these substances while considering their efficacy in treating a range of mental health conditions such as depression, anxiety disorders, and addiction. The resolution reflects a growing recognition of the potential therapeutic applications of these compounds, especially in light of research that suggests they may offer substantial improvements over traditional treatments for certain mental health issues.
Contention
Despite its potential benefits, the bill may encounter opposition based on concerns about the safety and regulation of psilocybin and psilocin. Critics may argue about the implications of legalizing substances that have traditionally been classified as illegal drugs, citing potential risks associated with misuse or lack of adequate research. Moreover, discussions may arise around how such legislation could alter existing paradigms in mental healthcare and the ethical considerations of using psychedelic substances in treatment settings.
Requesting That A Task Force Be Convened To Develop A Norwegian-based Public Facility Model Designated To Ensure The Well-being And Safety Of Dementia Patients.
Requesting That A Task Force Be Convened To Develop A Norwegian-based Public Facility Model Designated To Ensure The Well-being And Safety Of Dementia Patients.
Requesting The Department Of Health's State Health Planning And Development Agency To Convene A Health Data Sharing Working Group To Accelerate And Expand The Sharing Of Real Time Health Information Among Health Care Entities And Government Agencies In The State.
Requesting The Office Of Planning And Sustainable Development To Convene A Working Group To Develop Recommendations To Expand Blue Carbon Initiatives In The State.
Requesting The Department Of Health To Convene A Stakeholder Working Group To Make Recommendations To Enhance Meaningful Access To Health Care In The State Through The Provision Of Language Assistance Services.
Requesting The State Health Planning And Development Agency To Convene A Health Information Data Sharing Working Group To Collaborate And Establish The Framework And Standards For Future Health Information Data Sharing Legislation.
Requesting The Department Of Health's State Health Planning And Development Agency To Convene A Health Data Sharing Working Group To Accelerate And Expand The Sharing Of Real Time Health Information Among Health Care Entities And Government Agencies In The State.
Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Requesting The Department Of Health To Convene A Medicinal Psilocybin And Psilocin Working Group To Examine The Medicinal And Therapeutic Effects Of Psilocybin And Psilocin And Develop A Long-term Strategic Plan To Ensure The Availability Of Medicinal Psilocybin And Psilocin Or Psilocybin-based And Psilocin-based Products That Are Safe, Accessible, And Affordable For Eligible Adult Patients.
Controlled dangerous substances; authorizing certain research and clinical trials related to psilocybin and psilocin; requiring registration; providing certain immunities.
Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients.
Requesting The Department Of Health To Convene A Medicinal Psychedelics Right-to-try Task Force To Explore The Development Of A Program For Qualifying Terminally Ill Patients.